Oct. 3 at 4:27 PM
$DAWN's Chief Development Officer Davy Chiodin Will Join the
FDA & Osteosarcoma Institute Workshop, Advancing Osteosarcoma Drug Development – Connecting Research and Regulatory Pathways for Improved Outcomes on Oct 10, 2025 at 3:00-4:00 PM.
$AZN $GSK $EXEL
https://fda.gov/news-events/fda-meetings-conferences-and-workshops/fdathe-osteosarcoma-institute-osi-workshop-advancing-osteosarcoma-drug-development-connecting
SESSION 7: The Path Forward
• How advocacy, academic, industry, and regulatory parties can collaborate on a path forward through specific product development, trial design, endpoints, combination, and platform trials.
Panelists will discuss opportunities for advocacy, academia, industry and regulatory parties to collaborate on a path forward to advance osteosarcoma drug development, improve trial design, and drive better outcomes for patients.
https://www.linkedin.com/company/dayonebio/posts/
